ROC2 Antibody

What is ROC2/SAG/RBX2 and why is it important in research?

ROC2 (RING of Cullin-2), also known as Sensitive to Apoptosis Gene (SAG) or RBX2, is a RING-finger protein that functions as a critical component of SCF (Skp1-Cullin1-F-box-protein) E3 ubiquitin ligases. It mediates the transfer of ubiquitin molecules to substrates for subsequent recognition and degradation by proteasomes .

ROC2/SAG was originally cloned as a redox-inducible antioxidant protein and was later characterized for its role in protein degradation . As a protein kinase, it serves as a key regulator of actin cytoskeleton and cell polarity. It is involved in:

• Regulation of smooth muscle contraction

• Actin cytoskeleton organization

• Stress fiber and focal adhesion formation

• Neurite retraction

• Cell adhesion and motility via phosphorylation of multiple target proteins

Research significance: Overexpression of ROC2/SAG inhibits apoptosis induced by many stimuli both in vitro and in vivo. Its mRNA has been found to be overexpressed in human lung tumor tissues with correlation to poor patient survival, making it a promising target for anticancer therapies .

What applications are ROC2 antibodies commonly used for in research?

ROC2/SAG antibodies have been validated for multiple research applications:

When selecting applications, researchers should verify that the specific antibody has been validated for their intended use, as performance can vary significantly between applications .

How should researchers validate ROC2 antibodies before experimental use?

Proper antibody validation is critical for experimental reliability. For ROC2/SAG antibodies, validation should include:

• Positive and negative controls: Test antibody against:

  • Cell lines known to express ROC2/SAG (e.g., HeLa, HepG2)

  • Knockout or siRNA knockdown samples for negative controls

• Molecular weight verification: Confirm that detected bands match expected molecular weight (approximately 160 kDa for ROCK2)

• Cross-reactivity testing: Verify specificity against related proteins, particularly ROC1/RBX1 which shares structural similarity

• Application-specific validation:

  • For Western blots: Confirm single band of appropriate molecular weight

  • For IHC/ICC: Include peptide competition assays to confirm specificity

• Multiple antibody approach: Compare results using antibodies against different epitopes of ROC2/SAG

According to the International Working Group for Antibody Validation (IWGAV), at least one of the following "pillars" of validation should be employed:

• Genetic strategies (gene knockout or knockdown)

• Orthogonal strategies (comparison with non-antibody-based methods)

• Independent antibody strategies (two or more antibodies to different epitopes)

• Expression of tagged proteins

• Immunocapture followed by mass spectrometry

What are the key epitopes targeted by commercially available ROC2 antibodies?

Commercial ROC2/SAG antibodies target different epitopes, which affects their performance in various applications:

The choice of epitope can significantly impact antibody performance. For instance, antibodies targeting the RING domain may be optimal for studying E3 ligase interactions, while C-terminal antibodies might better detect the protein in fixed tissue samples .

What experimental controls are essential when using ROC2 antibodies?

To ensure reliable results with ROC2/SAG antibodies, researchers should implement these essential controls:

• Positive controls:

  • Cell lines with known ROC2/SAG expression (HepG2, HeLa, mouse/rat brain lysates)

  • Recombinant ROC2/SAG protein

• Negative controls:

  • siRNA or shRNA knockdown samples

  • Isotype-matched irrelevant antibodies for immunostaining

  • Secondary antibody-only controls

• Antigen competition:

  • Pre-incubation of antibody with immunizing peptide to confirm specificity

• Loading controls for Western blots:

  • Housekeeping proteins (β-actin, GAPDH)

  • Total protein stains for normalization

• Multiple antibody verification:

  • Compare results using antibodies targeting different epitopes

These controls address common issues such as non-specific binding, which is particularly important as some studies have shown conflicting results when using different ROC2/SAG antibodies .

How can researchers accurately differentiate between ROC1 and ROC2 in experimental systems?

Differentiating between the highly similar RING E3 ligase components ROC1 (RBX1) and ROC2 (RBX2/SAG) requires careful experimental design:

• Epitope selection strategy:

  • Target regions with lowest sequence homology between ROC1 and ROC2

  • Commercial antibodies specifically validated against both proteins should be used

  • Verify specificity through immunoblotting against recombinant ROC1 and ROC2 proteins

• Immunoprecipitation approach:

  • Sequential immunoprecipitation with antibodies specific to each protein

  • Mass spectrometry verification of pulled-down proteins

  • Analysis of distinct interaction partners (ROC1 and ROC2 associate with different Cullin proteins)

• Expression profiling:

  • qPCR analysis with highly specific primers to distinguish mRNA expression

  • Simultaneous knockdown experiments to verify antibody specificity

  • Comparison of expression patterns across tissues (ROC2/SAG shows tissue-specific expression patterns different from ROC1)

In one validation study, researchers found that using antibodies targeting the divergent C-terminal regions provided better discrimination between these related proteins than antibodies against the more conserved RING domains .

What methodological approaches can be used to study ROC2's role in E3 ligase activity?

Advanced methodological approaches to investigate ROC2/SAG E3 ligase function include:

• In vitro ubiquitination assays:

  • Reconstitute purified components (E1, E2, ROC2-containing E3 complex, substrate, ubiquitin)

  • Detect ubiquitinated products via Western blot with substrate-specific and ubiquitin antibodies

  • Use ROC2 antibodies for immunodepletion studies to confirm specificity

• Substrate identification approaches:

  • Immunoprecipitation of ROC2 complexes followed by mass spectrometry

  • Tandem ubiquitin-binding entity (TUBE) pulldowns in cells with ROC2 manipulation

  • Proteomics analysis after ROC2 knockdown/overexpression

• Cell-based degradation assays:

  • Pulse-chase analysis of substrate half-life with ROC2 manipulation

  • Cycloheximide chase experiments (e.g., demonstrated for NOXA, showing ROC2 overexpression shortened its half-life from 2.7 to 1.2 hours)

  • Fluorescent timer fusion proteins to monitor substrate turnover

• Structural analysis:

  • Co-immunoprecipitation using antibodies against different ROC2 domains

  • Proximity ligation assays to verify in situ interactions

  • Hydrogen-deuterium exchange mass spectrometry to map binding interfaces

The case of NOXA protein provides an excellent example: researchers demonstrated through antibody-based techniques that ROC2/SAG overexpression significantly shortened NOXA's half-life, while ROC2/SAG silencing extended it, establishing NOXA as a novel substrate of ROC2/SAG E3 ligase .

What approaches help resolve conflicting results when different ROC2 antibodies yield inconsistent findings?

Researchers frequently encounter inconsistent results when using different antibodies against the same target. To resolve conflicts with ROC2/SAG antibodies:

• Comprehensive antibody validation:

  • Test multiple antibodies targeting different epitopes of ROC2

  • Document exact clone numbers, catalog numbers, and dilutions used

  • Verify each antibody against known positive and negative controls

• Orthogonal method verification:

  • Complement antibody-based detection with non-antibody methods

  • Verify protein expression with mRNA quantification

  • Use ROC2/SAG-GFP fusion proteins as internal standards

• Detailed epitope mapping:

  • Identify exact binding sites of each antibody

  • Consider whether post-translational modifications may affect epitope accessibility

  • Test antibodies under various sample preparation conditions (native vs. denatured)

• Systematic application-specific testing:

  • Evaluate each antibody in multiple applications (WB, IHC, IP)

  • Document differences in fixation methods, incubation times, and buffer conditions

  • Compare performance across different tissues/cell types

• Independent laboratory verification:

  • Have conflicting results independently replicated

  • Consider interlaboratory studies with standardized protocols

A case study examining ROR2 detection found that among three commercially available antibodies, only one bound specifically to ROR2, another cross-reacted with other proteins, and the third failed to detect ROR2 at all . This highlights the importance of rigorous validation practices for all antibodies, including those targeting ROC2/SAG.

How can researchers optimize detection of post-translational modifications of ROC2 using antibody-based techniques?

Detecting post-translational modifications (PTMs) of ROC2/SAG requires specialized approaches:

• Phospho-specific antibody methodology:

  • Use antibodies specifically raised against phosphorylated epitopes (e.g., phospho-Y722 ROCK2)

  • Validate with phosphatase treatment of samples as negative controls

  • Compare results with general ROC2 antibodies to determine modification stoichiometry

• Enrichment strategies for PTM detection:

  • Phospho-protein enrichment using TiO₂ or IMAC prior to immunoblotting

  • SUMOylation/ubiquitination enrichment using tandem ubiquitin-binding entities

  • Immunoprecipitation under non-denaturing conditions to preserve modifications

• 2D gel electrophoresis approach:

  • Separate protein isoforms based on charge and mass

  • Western blot with ROC2/SAG antibodies

  • Identify shifts corresponding to PTMs

• Proteomic verification methods:

  • Immunoprecipitate ROC2/SAG and analyze by mass spectrometry

  • Identify specific modification sites and types

  • Use multiple proteases to ensure complete sequence coverage

• Conformation-specific detection:

  • Use antibodies that recognize specific conformational states induced by PTMs

  • Preserve native protein structure during sample preparation

  • Apply proximity ligation assays to detect interactions dependent on modifications

Research has demonstrated that phosphorylation of ROCK2 at Y722 affects its function in regulating myosin light chain phosphorylation and vascular contractility . Similar approaches can be applied to study other PTMs of ROC2/SAG that may regulate its E3 ligase activity.

What are the best methodological approaches for studying ROC2's role in cancer development using antibody-based techniques?

For investigating ROC2/SAG in cancer research, several sophisticated methodological approaches are recommended:

• Tissue microarray (TMA) analysis:

  • Evaluate ROC2/SAG expression across multiple tumor types and normal tissues

  • Use validated antibodies with proper controls

  • Perform quantitative image analysis with standardized scoring systems

  • One study demonstrated ROC2/SAG protein overexpression in multiple cancer types, particularly lung cancer, showing its potential as a biomarker

• Patient-derived xenograft (PDX) models:

  • Use antibodies to monitor ROC2/SAG expression in PDX models

  • Correlate expression with therapeutic responses

  • Compare with primary tumor immunostaining to verify model fidelity

• Functional analysis in cancer cells:

  • siRNA/shRNA knockdown followed by antibody detection of potential substrates

  • Clonogenic survival assays after manipulation of ROC2/SAG expression

  • In vivo tumor growth assessment using orthotopic models

  • Research showed SAG silencing inhibited in vivo tumor growth by 50% in an orthotopic pancreatic cancer model

• Mechanistic studies:

  • Immunoprecipitation to identify cancer-specific ROC2/SAG interaction partners

  • Analyze post-translational modifications in cancer vs. normal cells

  • Proximity ligation assays to verify protein-protein interactions in situ

• Therapy response prediction:

  • Correlate ROC2/SAG expression with radiation or chemotherapy sensitivity

  • Use as a potential predictive biomarker for treatment selection

  • Studies showed SAG silencing sensitized radioresistant cancer cells to radiation with sensitizing enhancement ratios of 1.28-1.43

Studies have demonstrated that ROC2/SAG silencing selectively inhibits cancer cell proliferation (but not normal cells), suppresses in vivo tumor growth, and sensitizes radiation-resistant cancer cells to radiation, establishing ROC2/SAG as a promising anticancer target .

What are the most common technical issues when using ROC2 antibodies and how can they be resolved?

When working with ROC2/SAG antibodies, researchers frequently encounter these technical challenges:

One research group found that for detecting ROR2 (another cancer-related protein), only one of three commercially available antibodies provided specific detection, highlighting the importance of thorough validation . For ROC2/SAG antibodies, similar challenges may arise, necessitating rigorous validation and optimization.

How can researchers ensure reproducibility when using ROC2 antibodies across different studies?

To maximize reproducibility with ROC2/SAG antibodies across studies:

• Detailed documentation requirements:

  • Report complete antibody information: supplier, catalog number, lot number, clone for monoclonals, and RRID when available

  • Document all experimental conditions: dilutions, incubation times/temperatures, buffer compositions

  • Maintain comprehensive lab records of optimization experiments

• Standardized validation protocols:

  • Implement systematic validation for each new antibody lot

  • Use the same positive and negative controls consistently

  • Maintain reference samples for inter-experimental comparisons

• Sample preparation consistency:

  • Standardize lysis buffers, fixation protocols, and processing methods

  • Document protein quantification methods and loading amounts

  • Consider effects of sample storage on epitope integrity

• Technical replicate considerations:

  • Perform both technical and biological replicates

  • Include inter-lot comparisons when changing antibody batches

  • Use quantitative analysis methods with appropriate statistical tests

• Data sharing practices:

  • Share detailed protocols through repositories like protocols.io

  • Deposit full, unprocessed images in data repositories

  • Consider using standardized reporting formats like ARRIVE guidelines

The International Working Group for Antibody Validation (IWGAV) has proposed guidelines that emphasize transparency and multiple validation methods to enhance reproducibility . Applying these principles to ROC2/SAG antibody use will improve consistency across studies.

What quantification methods are most appropriate for ROC2 expression analysis in different experimental systems?

Accurate quantification of ROC2/SAG expression requires selecting appropriate methods based on the experimental context:

• Western blot quantification:

  • Densitometry with appropriate normalization to loading controls

  • Consider total protein normalization methods (REVERT, Ponceau S)

  • Establish linear dynamic range for accurate quantification

  • Use three technical replicates minimum for statistical analysis

• Immunohistochemistry quantification:

  • Semi-quantitative scoring systems (H-score, Allred score)

  • Digital image analysis with automated detection algorithms

  • Multiplex approaches to analyze ROC2/SAG alongside other markers

  • Category systems based on staining intensity (e.g., groups 1-4 as used in one ROC2/SAG study)

• Flow cytometry approaches:

  • Mean/median fluorescence intensity measurements

  • Comparison to isotype controls and fluorescence-minus-one controls

  • Quantitative flow cytometry with reference beads for absolute quantification

• Quantitative microscopy:

  • Fluorescence intensity measurement with appropriate background correction

  • 3D confocal analysis for volumetric quantification

  • High-content imaging systems for automated analysis

• mRNA-protein correlation analysis:

  • Combine RT-qPCR with protein quantification

  • Account for potential post-transcriptional regulation

  • Use as orthogonal validation of antibody-based results

For comparative studies, it's crucial to use consistent quantification methods across all samples. One study analyzing ROC2/SAG in lung cancer classified samples into four groups based on staining intensity, finding that most tumor tissues had high ROC2/SAG staining (groups 3 and 4) compared to normal tissues (groups 1 and 2) .

How can ROC2 antibodies be utilized in studying the relationship between redox signaling and ubiquitination pathways?

ROC2/SAG was originally identified as a redox-inducible antioxidant protein before its role in ubiquitination was established, making it uniquely positioned at the intersection of these pathways:

• Dual-function analysis methods:

  • Co-immunoprecipitation of ROC2/SAG under varying oxidative conditions

  • Assess changes in E3 ligase activity following oxidative stress

  • Monitor ROC2/SAG subcellular localization shifts during redox signaling

• Redox-dependent substrate identification:

  • Compare ROC2/SAG-associated proteins under normal vs. oxidative stress

  • Analyze ubiquitination patterns of substrates during redox signaling

  • Use redox-sensitive fluorescent proteins fused to potential substrates

• Mechanistic investigation approaches:

  • Site-directed mutagenesis of redox-sensitive residues followed by antibody detection

  • Proximity-based labeling techniques to capture transient interactions

  • Hydrogen peroxide gradient experiments to determine sensitivity thresholds

• Therapeutic targeting assessment:

  • Evaluate effects of antioxidants on ROC2/SAG-mediated ubiquitination

  • Test redox-modulating compounds for effects on substrate degradation

  • Monitor ROC2/SAG expression during treatment with pro-oxidants

• Pathophysiological models:

  • Analyze ROC2/SAG function in ischemia/reperfusion models

  • Study ROC2/SAG in neurodegenerative diseases with redox components

  • Investigate cancer models where both pathways are dysregulated

Research has demonstrated that ROC2/SAG overexpression protects cells from damage induced by various redox compounds, suggesting its critical role at the interface of redox regulation and protein degradation . This dual functionality makes it a particularly interesting target for therapeutic development.

What are the cutting-edge approaches for using ROC2 antibodies in high-throughput and single-cell analyses?

Advanced technological applications of ROC2/SAG antibodies include:

• Single-cell proteomics approaches:

  • Mass cytometry (CyTOF) integration of ROC2/SAG antibodies

  • Microfluidic antibody capture for single-cell protein quantification

  • Imaging mass cytometry for spatial single-cell ROC2/SAG detection

• High-content screening methodologies:

  • Automated microscopy with ROC2/SAG antibodies for drug screening

  • Cell painting approaches integrating ROC2/SAG with morphological features

  • Machine learning analysis of ROC2/SAG subcellular distribution patterns

• Spatial proteomics innovations:

  • Highly multiplexed imaging using cyclic immunofluorescence

  • CODEX or 4i multiplex imaging platforms for tissue analysis

  • Spatial transcriptomics combined with ROC2/SAG protein detection

• Miniaturized assay platforms:

  • Reverse phase protein arrays for high-throughput ROC2/SAG quantification

  • Digital ELISA approaches for ultrasensitive detection

  • Antibody arrays for parallel analysis of ROC2/SAG and interacting partners

• Dynamic live-cell applications:

  • Anti-ROC2/SAG nanobodies for live-cell imaging

  • FRET-based sensors to monitor ROC2/SAG interactions in real-time

  • Optogenetic tools combined with antibody detection

These emerging approaches allow researchers to explore ROC2/SAG function with unprecedented resolution and throughput, facilitating deeper understanding of its roles in both physiological and pathological contexts .

How can researchers effectively use ROC2 antibodies to investigate its potential as a therapeutic target?

ROC2/SAG has emerged as a promising therapeutic target, particularly in cancer treatment. Researchers can use antibodies to advance this field through:

• Target validation methodologies:

  • Immunohistochemical profiling across patient-derived samples to identify high-expression populations

  • Correlation of ROC2/SAG levels with clinical outcomes and treatment responses

  • Systematic analysis of normal tissue expression to predict potential toxicities

  • Studies have shown ROC2/SAG overexpression in multiple human tumor tissues compared to normal counterparts

• In vivo model development:

  • Monitor ROC2/SAG expression in PDX and organoid models using validated antibodies

  • Correlation of expression with response to targeted therapies

  • Use of inducible knockdown systems with antibody-based verification

  • Research demonstrated that ROC2/SAG silencing inhibited in vivo tumor growth in pancreatic cancer orthotopic models

• Mechanism-based combination approaches:

  • Identify synthetic lethal interactions through ROC2/SAG expression analysis

  • Monitor changes in substrate levels following ROC2/SAG inhibition

  • Evaluate effects on radioresistance and chemoresistance

  • Studies showed ROC2/SAG silencing sensitized radioresistant cancer cells to radiation

• Biomarker development strategies:

  • Standardize ROC2/SAG detection methods for patient stratification

  • Correlate ROC2/SAG expression with specific substrates as companion diagnostics

  • Develop multiplexed approaches to analyze ROC2/SAG pathway activation

• Target engagement assessment:

  • Use antibodies to verify target engagement of ROC2/SAG inhibitors

  • Monitor changes in substrate accumulation as pharmacodynamic markers

  • Analyze feedback mechanisms following ROC2/SAG inhibition

Research has established several key properties that make ROC2/SAG an attractive target: its overexpression in cancer tissues, association with poor prognosis, cancer-selective effects when inhibited, and role in treatment resistance .